To further the development of COVID-19 vaccines, biotechnology companies have been creating exosome-based vaccines, such as that of Capricor Therapeutics, containing mRNA for the full-length S protein and modified S, N, M, and E proteins, Allele Biotechnology and Pharmaceuticals’ mRNA-based vaccine, and the Ciloa’s CoVEVax vaccine, which consists of EVs containing the full S protein. The gene discussed is PROS1; the disease is COVID-19.